CoChat

Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation

Zerra, Patricia E., Arthur, Connie M., Chonat, Satheesh, Maier, Cheryl L., Mener, Amanda, Shin, Sooncheon, Allen, Jerry William L., Baldwin, W. Hunter, Cox, Courtney, Verkerke, Hans, Jajosky, Ryan P., Tormey, Christopher A., Meeks, Shannon L., Stowell, Sean R. · 2020 · Frontiers in Immunology
Cited by 18

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2020.00905

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 98

  1. Kulkarni, 2011, Pediatric hemophilia: a review, Semin Thromb Hemost., 37, 737, 10.1055/s-0031-1297164 · doi:10.1055/s-0031-1297164
  2. Zimmerman, 2013, Hemophilia: in review, Pediatr Rev., 34, 289, 10.1542/pir.34-7-289 · DOI
  3. Ehrenforth, 1992, Factor VIII inhibitors in haemophiliacs, Lancet., 340, 253, 10.1016/0140-6736(92)90530-G · doi:10.1016/0140-6736(92)90530-g
  4. Ehrenforth, 1992, Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs, Lancet., 339, 594, 10.1016/0140-6736(92)90874-3 · DOI · Paper page
  5. Aledort, 2004, Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity, J Thromb Haemost., 2, 1700, 10.1111/j.1538-7836.2004.00944.x · DOI · Paper page
  6. Lollar, 2004, Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX, J Thromb Haemost., 2, 1082, 10.1111/j.1538-7836.2004.00802.x · DOI
  7. Meeks, 2007, Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation, Blood., 110, 4234, 10.1182/blood-2007-06-096842 · DOI
  8. Kempton, 2014, Toward optimal therapy for inhibitors in hemophilia, Blood., 124, 3365, 10.1182/blood-2014-05-577643 · DOI
  9. Kempton, 2009, How we treat a hemophilia A patient with a factor VIII inhibitor, Blood., 113, 11, 10.1182/blood-2008-06-160432 · DOI · Paper page
  10. Lorenzo, 2001, Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age, Br J Haematol., 113, 600, 10.1046/j.1365-2141.2001.02828.x · DOI · Paper page
  11. White, 2005, Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?, J Thromb Haemost., 3, 1676, 10.1111/j.1538-7836.2005.01375.x · DOI
  12. Lillicrap, 2006, The role of immunomodulation in the management of factor VIII inhibitors, Hematology Am Soc Hematol Educ Program., 2006, 421, 10.1182/asheducation-2006.1.421 · doi:10.1182/asheducation-2006.1.421
  13. Di Michele, 2011, Immune tolerance induction in haemophilia: evidence and the way forward, J Thromb Haemost., 9, 216, 10.1111/j.1538-7836.2011.04349.x · DOI
  14. Moorehead, 2015, Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor, J Pediatr Hematol Oncol., 37, e220, 10.1097/MPH.0000000000000287 · doi:10.1097/mph.0000000000000287
  15. Valentino, 2015, US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors, Haemophilia., 21, 559, 10.1111/hae.12730 · DOI
  16. Aledort, 2019, Factor VIII replacement is still the standard of care in haemophilia A, Blood Transfus., 17, 479, 10.2450/2019.0211-19 · DOI
  17. Rodriguez-Merchan, 2019, Emicizumab: review of the literature and critical appraisal, Haemophilia., 25, 11, 10.1111/hae.13641 · DOI
  18. Yada, 2019, Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations, J Blood Med., 10, 171, 10.2147/JBM.S175952 · DOI
  19. Navarrete, 2009, Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A, J Thromb Haemost., 7, 1816, 10.1111/j.1538-7836.2009.03571.x · DOI
  20. Zerra, 2017, Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A, Blood., 130, 2559, 10.1182/blood-2017-05-782912 · DOI
  21. Ettinger, 2009, Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses, Blood., 114, 1423, 10.1182/blood-2009-01-200725 · DOI · Paper page
  22. Gupta, 2015, Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance, Sci Transl Med., 7, 275ra221, 10.1126/scitranslmed.aaa1957 · DOI
  23. Kim, 2015, Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses, Blood., 125, 1107, 10.1182/blood-2014-04-566786 · DOI · Paper page
  24. Biswas, 2017, Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin, Thromb Haemost., 117, 33, 10.1160/TH16-05-0404 · DOI
  25. Rayes, 2018, Complement C3 is a novel modulator of the anti-factor VIII immune response, Haematologica., 103, 351, 10.3324/haematol.2017.165720 · doi:10.3324/haematol.2017.165720
  26. Jing, 2019, Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice, Blood Adv., 3, 3099, 10.1182/bloodadvances.2019000650 · DOI
  27. Janeway, 1989, Approaching the asymptote? Evolution and revolution in immunology, Cold Spring Harb Symp Quant Biol., 54, 1, 10.1101/SQB.1989.054.01.003 · DOI · Paper page
  28. Aderem, 2000, Toll-like receptors in the induction of the innate immune response, Nature., 406, 782, 10.1038/35021228 · DOI · Paper page
  29. Medzhitov, 2000, Innate immune recognition: mechanisms and pathways, Immunol Rev., 173, 89, 10.1034/j.1600-065X.2000.917309.x · DOI · Paper page
  30. Gallucci, 2001, Danger signals: SOS to the immune system, Curr Opin Immunol., 13, 114, 10.1016/S0952-7915(00)00191-6 · DOI · Paper page
  31. Matzinger, 2002, The danger model: a renewed sense of self, Science., 296, 301, 10.1126/science.1071059 · DOI · Paper page
  32. O'Hagan, 2003, Recent advances in the discovery and delivery of vaccine adjuvants, Nat Rev Drug Discov., 2, 727, 10.1038/nrd1176 · DOI · Paper page
  33. Takeda, 2003, Toll-like receptors, Annu Rev Immunol., 21, 335, 10.1146/annurev.immunol.21.120601.141126 · DOI · Paper page
  34. Erlandsson Harris, 2004, Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator, Eur J Immunol., 34, 1503, 10.1002/eji.200424916 · DOI · Paper page
  35. Zhang, 2011, Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice, Blood., 117, 2223, 10.1182/blood-2010-06-293324 · DOI
  36. Meeks, 2012, A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function, Blood., 120, 2512, 10.1182/blood-2012-02-412361 · DOI
  37. Chao, 2016, Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene, J Thromb Haemost., 14, 346, 10.1111/jth.13202 · DOI
  38. Hartholt, 2017, Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells, J Thromb Haemost., 15, 329, 10.1111/jth.13570 · doi:10.1111/jth.13570
  39. Vollack, 2017, Anti-FcgammaRIIB (CD32) antibodies differentially modulate murine FVIII-specific recall response in vitro, Scand J Immunol., 86, 91, 10.1111/sji.12573 · doi:10.1111/sji.12573
  40. Batsuli, 2018, Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model, J Thromb Haemost., 16, 1779, 10.1111/jth.14233 · DOI
  41. Nimmerjahn, 2006, Fcgamma receptors: old friends and new family members, Immunity., 24, 19, 10.1016/j.immuni.2005.11.010 · DOI · Paper page
  42. Yada, 2003, Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake, Cell Immunol., 225, 21, 10.1016/j.cellimm.2003.09.008 · DOI
  43. Liu, 2016, Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice, Blood., 128, 3159, 10.1182/blood-2016-06-724732 · DOI
  44. Stowell, 2013, Antigen modulation confers protection to red blood cells from antibody through Fcgamma receptor ligation, J Immunol., 191, 5013, 10.4049/jimmunol.1300885 · DOI
  45. Mener, 2018, Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses, JCI Insight., 3, e121631, 10.1172/jci.insight.121631 · DOI
  46. Kasper, 1975, Proceedings: A more uniform measurement of factor VIII inhibitors, Thromb Diath Haemorrh., 34, 612, 10.1055/s-0039-1689482 · DOI · Paper page
  47. Stowell, 2013, Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model, Blood., 122, 1494, 10.1182/blood-2013-03-488874 · DOI
  48. Stowell, 2014, Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies, Transfusion., 54, 179, 10.1111/trf.12217 · doi:10.1111/trf.12217
  49. Girard-Pierce, 2013, A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation, Blood., 122, 1793, 10.1182/blood-2013-06-508952 · doi:10.1182/blood-2013-06-508952
  50. Patel, 2018, Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion, Front Immunol., 9, 2516, 10.3389/fimmu.2018.02516 · DOI
  51. Sarma, 2011, The complement system, Cell Tissue Res., 343, 227, 10.1007/s00441-010-1034-0 · DOI · Paper page
  52. You, 2011, Marginal zone B cells regulate antigen capture by marginal zone macrophages, J Immunol, 186, 2172, 10.4049/jimmunol.1002106 · DOI · Paper page
  53. Seiler, 1997, Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection, Eur J Immunol., 27, 2626, 10.1002/eji.1830271023 · DOI · Paper page
  54. Aichele, 2003, Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses, J Immunol., 171, 1148, 10.4049/jimmunol.171.3.1148 · DOI · Paper page
  55. Malkiel, 2009, The loss and gain of marginal zone and peritoneal B cells is different in response to relapsing fever and Lyme disease Borrelia, J Immunol., 182, 498, 10.4049/jimmunol.182.1.498 · doi:10.4049/jimmunol.182.1.498
  56. Attanavanich, 2004, Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells, J Immunol., 172, 803, 10.4049/jimmunol.172.2.803 · DOI · Paper page
  57. Cerutti, 2013, Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes, Nat Rev Immunol., 13, 118, 10.1038/nri3383 · DOI · Paper page
  58. Martin, 2002, Marginal-zone B cells, Nat Rev Immunol., 2, 323, 10.1038/nri799 · DOI · Paper page
  59. Cinamon, 2008, Follicular shuttling of marginal zone B cells facilitates antigen transport, Nat Immunol., 9, 54, 10.1038/ni1542 · DOI · Paper page
  60. Snapper, 1993, Comparative in vitro analysis of proliferation, Ig secretion, and Ig class switching by murine marginal zone and follicular B cells, J Immunol., 150, 2737, 10.4049/jimmunol.150.7.2737 · DOI
  61. Heyman, 1990, The immune complex: possible ways of regulating the antibody response, Immunol Today., 11, 310, 10.1016/0167-5699(90)90126-T · doi:10.1016/0167-5699(90)90126-t
  62. Heyman, 2000, Regulation of antibody responses via antibodies, complement, and Fc receptors, Annu Rev Immunol., 18, 709, 10.1146/annurev.immunol.18.1.709 · DOI · Paper page
  63. Jancar, 2005, Immune complex-mediated tissue injury: a multistep paradigm, Trends Immunol., 26, 48, 10.1016/j.it.2004.11.007 · DOI
  64. Nimmerjahn, 2008, Fcgamma receptors as regulators of immune responses, Nat Rev Immunol., 8, 34, 10.1038/nri2206 · DOI · Paper page
  65. Ahearn, 1996, Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen, Immunity., 4, 251, 10.1016/S1074-7613(00)80433-1 · DOI · Paper page
  66. Fischer, 1998, Dependence of germinal center B cells on expression of CD21/CD35 for survival, Science., 280, 582, 10.1126/science.280.5363.582 · DOI · Paper page
  67. Da Costa, 1999, Humoral response to herpes simplex virus is complement-dependent, Proc Natl Acad Sci USA., 96, 12708, 10.1073/pnas.96.22.12708 · DOI · Paper page
  68. Carroll, 2012, Regulation of humoral immunity by complement, Immunity., 37, 199, 10.1016/j.immuni.2012.08.002 · DOI · Paper page
  69. Fischer, 1996, Regulation of the B cell response to T-dependent antigens by classical pathway complement, J Immunol., 157, 549, 10.4049/jimmunol.157.2.549 · DOI · Paper page
  70. Molina, 1996, Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2, Proc Natl Acad Sci USA., 93, 3357, 10.1073/pnas.93.8.3357 · DOI · Paper page
  71. Vogel, 2010, Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion, Toxicon., 56, 1198, 10.1016/j.toxicon.2010.04.007 · DOI · Paper page
  72. Samuels, 2019, Alternative complement pathway activation provokes a hypercoagulable state with diminished fibrinolysis, Shock., 53, 560, 10.1097/SHK.0000000000001437 · DOI
  73. Kock, 2004, Structure and function of recombinant cobra venom factor, J Biol Chem., 279, 30836, 10.1074/jbc.M403196200 · DOI
  74. Lambris, 1988, The multifunctional role of C3, the third component of complement, Immunol Today., 9, 387, 10.1016/0167-5699(88)91240-6 · DOI · Paper page
  75. Nordahl, 2004, Activation of the complement system generates antibacterial peptides, Proc Natl Acad Sci USA., 101, 16879, 10.1073/pnas.0406678101 · DOI · Paper page
  76. Kang, 2006, A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q, Cell., 125, 47, 10.1016/j.cell.2006.01.046 · DOI · Paper page
  77. Rittirsch, 2008, Functional roles for C5a receptors in sepsis, Nat Med., 14, 551, 10.1038/nm1753 · DOI · Paper page
  78. Ward, 2009, Functions of C5a receptors, J Mol Med., 87, 375, 10.1007/s00109-009-0442-7 · DOI · Paper page
  79. Ing, 2018, Absence of a neutralizing antibody response to humanized cobra venom factor in mice, Mol Immunol., 97, 1, 10.1016/j.molimm.2018.02.018 · doi:10.1016/j.molimm.2018.02.018
  80. Shushakova, 2002, C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease, J Clin Invest., 110, 1823, 10.1172/JCI16577 · DOI · Paper page
  81. Zaal, 2019, Differential effects of anaphylatoxin C5a on antigen presenting cells, roles for C5aR1 and C5aR2, Immunol Lett., 209, 45, 10.1016/j.imlet.2019.03.014 · DOI
  82. Ricklin, 2010, Complement: a key system for immune surveillance and homeostasis, Nat Immunol., 11, 785, 10.1038/ni.1923 · DOI · Paper page
  83. Reis, 2019, New insights into the immune functions of complement, Nat Rev Immunol., 19, 503, 10.1038/s41577-019-0168-x · DOI · Paper page
  84. Valdez, 2014, Influence of the microbiota on vaccine effectiveness, Trends Immunol., 35, 526, 10.1016/j.it.2014.07.003 · DOI
  85. Lazar, 2018, Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer, Front Immunol., 9, 1830, 10.3389/fimmu.2018.01830 · DOI · Paper page
  86. Lai, 2016, Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A, Blood., 127, 3439, 10.1182/blood-2015-11-679282 · DOI
  87. Patel, 2018, Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice, Blood Adv., 2, 105, 10.1182/bloodadvances.2017010124 · DOI
  88. Stowell, 2012, Initiation and regulation of complement during hemolytic transfusion reactions, Clin Dev Immunol., 2012, 307093, 10.1155/2012/307093 · DOI
  89. Calabro, 2016, Bridging channel dendritic cells induce immunity to transfused red blood cells, J Exp Med., 213, 887, 10.1084/jem.20151720 · DOI
  90. Eisenbarth, 2019, Dendritic cell subsets in T cell programming: location dictates function, Nat Rev Immunol., 19, 89, 10.1038/s41577-018-0088-1 · DOI · Paper page
  91. Nickel, 2016, Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series, Transfusion., 56, 107, 10.1111/trf.13379 · DOI
  92. Chonat, 2018, Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease, Haematologica., 103, e483, 10.3324/haematol.2018.194670 · DOI
  93. Dean, 2018, Multiple hemolytic transfusion reactions misinterpreted as severe vaso-occlusive crisis in a patient with sickle cell disease, Transfusion., 59, 448, 10.1111/trf.15010 · DOI
  94. Dean, 2019, Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients, Transfusion., 59, 1698, 10.1111/trf.15227 · doi:10.1111/trf.15227
  95. Meinderts, 2017, Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease, Blood., 130, 2121, 10.1182/blood-2017-05-784876 · DOI
  96. Li, 2019, Fc gamma receptor polymorphisms modulated the vaccine effect on HIV-1 Risk in the HVTN 505 HIV vaccine trial, J Virol., 93, e02041, 10.1128/JVI.02041-18 · DOI
  97. Arthur, 2017, Antigen density dictates immune responsiveness following red blood cell transfusion, J Immunol., 198, 2671, 10.4049/jimmunol.1601736 · DOI
  98. Maier, 2018, Antibody-mediated immune suppression by antigen modulation is antigen-specific, Blood Adv., 2, 2986, 10.1182/bloodadvances.2018018408 · DOI

Cited by

See all 18

Metadata

Authors
Zerra, P. E., Arthur, C. M., Chonat, S., Maier, C. L., Mener, A., Shin, S., Allen, J. W. L., Baldwin, W. H., Cox, C., Verkerke, H., Jajosky, R. P., Tormey, C. A., Meeks, S. L., & Stowell, S. R.
Venue
Frontiers in Immunology
Published
2020-06-09
Volume
11
ISSN
1664-3224
Cited by
18
References
6
Funders
National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation. https://app.cochat.ai/papers/10.3389/fimmu.2020.00905
The paper
Zerra, P. E., Arthur, C. M., Chonat, S., Maier, C. L., Mener, A., Shin, S., Allen, J. W. L., Baldwin, W. H., Cox, C., Verkerke, H., Jajosky, R. P., Tormey, C. A., Meeks, S. L., & Stowell, S. R. (2020). Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.00905

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.